| 36th week of 2009 patent applcation highlights part 32 |
| Patent application number | Title | Published |
|---|
| 20090220539 | Recombinant Mononegaviral Virus Vectors - The invention relates to a recombinant Mononegavirales virus (MV) vector comprising a foreign gene that is flanked by non-coding regions of a MV virus gene. | 2009-09-03 |
| 20090220540 | Helicobacter System and Uses Thereof - based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, | 2009-09-03 |
| 20090220541 | EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES - A split influenza virus vaccine is adjuvanted with an oil-in-water emulsion that contains free surfactant in its aqueous phase. The free surfactant can continue to exert a “splitting effect” on the antigen, thereby disrupting any unsplit virions and/or virion aggregates that might be present. | 2009-09-03 |
| 20090220542 | VACCINE COMPRISED SPECIFICALLY OF PROTEIN SUBUNITS OF HUMAN IMMUNODEFICIENCY VIRUS'S GLYCOPROTEIN 120 PROBE TO PREVENT AND TREAT AN INFECTION CAUSED BY THE HUMAN IMMUNODEFICIENCY VIRUS - The human immunodeficiency virus poses a significant threat to the health and well being of the world's population. Current strategies utilized to eradicate this deadly pathogen have not been effective. A vaccine comprised solely of protein subunits of the glycoprotein 120 probe as the active ingredient, can be effective in stimulating an individual's immune system to repel an HIV infection. The protein subunit of the glycoprotein 120 probe extends from the surface of HIV and is the unique identifier of an HIV virion. When protein subunits of HIV's glycoprotein probe are exclusively presented to the immune system, the antibodies generated will neutralize the glycoprotein 120 probes located on the surface of HIV virions, such that the virus's virions then are incapable of engaging a T-Helper cell and thus the infectious threat posed by HIV is averted. | 2009-09-03 |
| 20090220543 | Expression of Proteins in Plants - The invention relates to a method of producing a HPV polypeptides and/or an influenza virus H5 polypeptide in a plant comprising the steps of cloning a HPV gene; and/or an influenza virus H5 gene or nucleic acid encoding their functional equivalents into a vector adapted to target components present in the plant, infiltrating at least a portion of the plant with the vector or transforming plant tissue with the vector so as to transiently express the HPV polypeptides and/or an influenza virus H5 polypeptide, and/or to create a transgenic plant; and recovering the HPV polypeptides and/or an influenza virus H5 polypeptide expressed by the plant. The invention further relates to vectors, transgenic plants or parts thereof and the progeny of such plants used in or which come about as a result of the method. | 2009-09-03 |
| 20090220544 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE - An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions. | 2009-09-03 |
| 20090220545 | Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen - An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant. | 2009-09-03 |
| 20090220546 | Adjuvanted influenza vaccines for pediatric use - An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus. | 2009-09-03 |
| 20090220547 | Reducing interference between oil-containing adjuvants and surfactant-containing antigens - Inclusion of fatty adjuvants in vaccine compositions can cause difficulties with certain antigenic components, particularly with antigens that include a surfactant component. A method for preparing an immunogenic composition comprising an antigen and a fatty adjuvant involves purification of the antigen substantially in the absence of surfactant. Where surfactants cannot be avoided, the following are combined: (i) an antigen component that includes a surfactant and (ii) a fatty adjuvant component, to give a composition in which the weight ratio of said fatty adjuvant to said surfactant is less than 1000:1. | 2009-09-03 |
| 20090220548 | Immunogenic Agents Against Burkholderia Psudomallei And/Or Burkholderia Mallei, Comprising Lipopolysaccharide, Capsular Polysaccharide And/Or Proteins From Burkholderia Pseudomallei - An immunogenic agent which comprises a killed strain of | 2009-09-03 |
| 20090220549 | REAGENTS FOR RECOMBINOGENIC ENGINEERING AND USE THEREOF - The present invention features homologous recombination methods and systems. The methods and systems promote highly efficient homologous recombination in cells (e.g., in prokaryotic cells). The methods and systems are useful, for example, in pharmaceutical drug development, vaccine development and cloning. | 2009-09-03 |
| 20090220550 | Vaccines for Mycoplasma bovis and methods of use - The invention of novel, effective vaccines against | 2009-09-03 |
| 20090220551 | CONCURRENT CHEMOTHERAPY AND IMMUNOTHERAPY - The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, in fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine. | 2009-09-03 |
| 20090220552 | FORMULATIONS CONTAINING PANTOPRAZOLE FREE ACID AND ITS SALTS - The invention relates to new formulations and dosage units of solid crystalline pantoprazole free acid and its salts (e.g., pantoprazole sodium sesquihydrate) that are resistant to gastric juice digestion and are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, and a process for making the same | 2009-09-03 |
| 20090220553 | Composition and Method for Inhibiting, Preventing, or Ameliorating Complications Associated With Ingestion of a Medicinal, Chemical, or Biological Substance or Agent - The application relates, in part, to a therapeutic composition comprising a pharmaceutically active agent and a diarrheagenic agent. | 2009-09-03 |
| 20090220554 | Transglutaminase Inhibitors and Methods of Use Thereof - Transglutaminase inhibitors and methods of use thereof are provided. | 2009-09-03 |
| 20090220555 | Sweat-Absorbing Cosmetic Product and Method for the Production Thereof - The invention relates to a—in particular—hydrous, sweat-absorbing cosmetic product, e.g. a deodorant, containing a sweat-absorbing complex. The invention also relates to a method for the production of said complex and said cosmetic product. | 2009-09-03 |
| 20090220556 | Nanodiamond uv protectant formulations - A cosmetic or sunscreen preparation provides transmission attenuation of ultraviolet A and ultraviolet B and ultraviolet C light when applied to human tissue to reduce exposure comprises a dispersion of an effective amount of diamond nanoparticle in a physiologically compatible medium, where the diamond nanoparticles have a size greater than about 60 nm. | 2009-09-03 |
| 20090220557 | EFFECT PIGMENT AND USE THEREOF IN COSMETICS AND IN THE FOOD AND PHARMACEUTICAL INDUSTRIES - The present invention relates to intensely coloured and light-stable effect pigments based on transparent, undoped SiO | 2009-09-03 |
| 20090220558 | EMULSION OF A LIQUID FLUORINATED OIL PHASE IN A LIQUID WATER PHASE - Emulsions of a liquid oil phase in a liquid water phase which comprise a) more than 50 weight percent of a hydrofluoroether, a perfluoroether or a combination thereof, based on the total weight of the emulsion, b) a surfactant, and c) water, are useful in a cosmetic formulation or a cosmetic concentrate. The hydrofluoroether is represented by formula (I) CnHmF0-O-CxHyFz wherein n is a number of 1 to 12, m is a number of 0 to 25, o is a number of 0 to 25, m+o=2n+1, x is a number of 1 to 12, y is a number of 0 to 25, z is a number of 0 to 25, and y+z=2x+1, provided that m and y are not simultaneously zero, and o and z are not simultaneously zero. | 2009-09-03 |
| 20090220559 | Multifunctional Solid Formulations for Water Conditioning - Solid formulations for use in water conditioning of circulating reservoirs, processes of preparing same and methods for water conditioning utilizing same are disclosed. The solid formulations combine a sanitizer with a bath salt and/or an odoriferous substance. | 2009-09-03 |
| 20090220560 | Nanosilver Coated Bacterial Cellulose - Nanosilver coated bacterial cellulose nanofiber and a method of producing the nanosilver coated bacterial cellulose nanofiber. The nanosilver coated bacterial cellulose nanofiber is produced by preparing a suspension of bacterial cellulose fibers, oxidizing bacterial cellulose fibers; adding the thio-group to the polymer backbone; reacting the resulting product with silver proteinate and enhancing the nanosilver particle size. The nanosilver coated bacterial cellulose nanofibers exhibit antimicrobial properties. | 2009-09-03 |
| 20090220561 | COMPOSITIONS COMPRISING NANOSTRUCTURES FOR CELL, TISSUE AND ARTIFICIAL ORGAN GROWTH, AND METHODS FOR MAKING AND USING SAME - The invention provides articles of manufacture comprising biocompatible nanostructures comprising nanotubes and nanopores for, e.g., organ, tissue and/or cell growth, e.g., for bone, kidney or liver growth, and uses thereof, e.g., for in vitro testing, in vivo implants, including their use in making and using artificial organs, and related therapeutics. The invention provides lock-in nanostructures comprising a plurality of nanopores or nanotubes, wherein the nanopore or nanotube entrance has a smaller diameter or size than the rest (the interior) of the nanopore or nanotube. The invention also provides dual structured biomaterial comprising micro- or macro-pores and nanopores. The invention provides biomaterials having a surface comprising a plurality of enlarged diameter nanopores and/or nanotubes. | 2009-09-03 |
| 20090220562 | Osteogenic and anti-adipogenic oxysterols - The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation are disclosed. Exemplary agents include oxysterols alone or in synergistic combinations, as well as hedgehog or Wnt signaling activators. The synergistic effects of oxysterols and bone morphogenic proteins are also disclosed. | 2009-09-03 |
| 20090220563 | ARTIFICIAL TOOTH MEDICATING APPARATUS FOR CONTROLLING, REGULATING, SENSING, AND RELEASING MEDICAL AGENTS INTO THE BODY - An artificial tooth apparatus for dispensing medicating agents to the body through the patient's jaw bone comprising a mechanical movement and kinetic mainspring winder, a tourbillon mechanism, a electronic regulator, and a pump mechanism arranged and configured to allow any medicating agent to be dispensed from the apparatus in a highly controlled and regulated manner according to input received by the electronic regulator and the patient's specific pharmacokinetic and pharmacodynamic attributes. Multiple artificial teeth or a comprehensive bridge with several chambers may be used in cases where a polypharmaceutical approach is needed. | 2009-09-03 |
| 20090220564 | METHODS OF TREATING AND PREVENTING ACUTE MYOCARDIAL INFARCTION - The present disclosure provides methods and compositions for treating coronary tissue damaged as a result of a cardiac disorder such as ischemia, acute myocardial infarction, vulnerable plaques, or reperfusion injury. Specifically, the cardiac disorder is treated using a multivalent molecule that is specific for a marker located, in or near the damaged coronary tissue and a marker located on a target cell (e.g., a stem cell). The multivalent molecule may be administered by intravenous injection, intra-arterial catheter, intramyocardial injection, or implantable device (e.g, stent). | 2009-09-03 |
| 20090220565 | METHOD FOR PRODUCING AUTONOMOUSLY CONTRACTING CARDIAC MUSCLE CELLS FROM ADULT STEM CELLS, IN PARTICULAR HUMAN ADULT STEM CELLS - A method for producing autonomously contractile heart muscle cells by cultivating and differentiating stem cells obtained from differentiated exocrine gland tissue of an organism is described. Various uses of the heart muscle cells, in particular in regenerative medicine, are also described. | 2009-09-03 |
| 20090220566 | BIOIMPLANTS FOR USE IN TISSUE GROWTH - Disclosed herein is an implant for use in stimulating tissue growth. The implant comprises a body with a body core and a body surface. The body is made from a non-hydrogel polymer material. A tissue growth stimulating material is disposed within the body core or deposited onto the body surface, in an amount which is sufficient to stimulate tissue growth within the body core or adjacent to the body surface. Also disclosed are implant bodies made from ceramic, metallic materials, and non-copper containing hydrogels. | 2009-09-03 |
| 20090220567 | Pure Populations of Astrocyte Restricted Precursor Cells and Methods for Isolation and Use Thereof - An isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for isolating and using these mammalian astrocyte restricted precursor cells are also provided. | 2009-09-03 |
| 20090220568 | METHODS FOR TREATING A STRICTURE WITH A BOTULINUM TOXIN - Methods of treating a urethral stricture in a patient. The methods can include the step of administering an therapeutically effective amount of a botulinum toxin directly to a urethra of the patient, for example by use of a stent from which the botulinum toxin can elute or diffuse, thereby treating the urethra stricture. | 2009-09-03 |
| 20090220569 | Prevascularized Constructs for Implantation to Provide Blood Perfusion - This application discloses methods and materials for preparing functional microvascular beds in the laboratory. These prevascularized constructs can be used to vascularize engineered tissue constructs or to revascularize damaged or diseased tissues or organs following implantation. The prevascularized constructs may also deliver genetically engineered gene products to the bloodstream. | 2009-09-03 |
| 20090220570 | Axon Regeneration with PKC Inhibitors - Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected. | 2009-09-03 |
| 20090220571 | SELF-EXPANDING DEVICES AND METHODS THEREFOR - Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here. | 2009-09-03 |
| 20090220572 | Injectable Combination Therapy for Eye Disorders - The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors. | 2009-09-03 |
| 20090220573 | Method, Device, and System for Delivery of Therapeutic Agents to the Eye - A method, device, and system for easier, consistent, and comfortable delivery of therapeutic agents to the front of the eye. | 2009-09-03 |
| 20090220574 | SURAMIN AND DERIVATIVES THEREOF AS TOPICAL MICROBICIDE AND CONTRACEPTIVE - The present invention is directed to methods of inhibiting STDs by topically administering suramin or a derivative thereof to actual or potential sites of infection, and methods of preventing pregnancy by topically applying suramin or a derivative thereof intravaginally. Suramin compositions that include an antimicrobial agent and/or a sperm-function inhibitor are also provided and may advantageously be used in the methods of the invention. A method of simultaneously inhibiting STDs and preventing pregnancy is also provided. Devices impregnated or coated with the topical suramin compositions are further disclosed and may be used to apply the compositions described herein. | 2009-09-03 |
| 20090220575 | COMPOSITIONS AND METHODS FOR THE SUSTAINED RELEASE OF BETA-ALANINE - Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. | 2009-09-03 |
| 20090220576 | EMULSION - The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester. | 2009-09-03 |
| 20090220577 | Moulded body for medically treating wounds - The invention relates to an absorbable and porous shaped article for the medical treatment of wounds, in particular large, deep wounds with heavy discharge, where the shaped article is in the form of a foam structure which includes a co- and/or terpolymer based on the monomers lactide, triethylene carbonate, ε-caprolactone and/or dioxan-2-one. | 2009-09-03 |
| 20090220578 | Hydrogel composition and method for making the same - Disclosed is a hydrogel composition comprising water, a first crosslinked polymer, and a second crosslinked polymer, wherein the first crosslinked polymer comprises poly(ethylene oxide) and the second crosslinked polymer comprises a hydrophilic polymer other than poly(ethylene oxide), wherein the first crosslinked polymer and the second crosslinked polymer form an interpenetrating network (IPN). The hydrogel of the present invention has an attractive combination of water absorption and compressive strength. The hydrogel composition finds use as a drug delivery device. The invention also provides a method of preparing such hydrogel composition. | 2009-09-03 |
| 20090220579 | Gelatin Non-Woven Structures Produced by a Non-Toxic Dry Solvent Spinning Process - The present application discloses an alternative method for the formation of non-woven with fibers in the 1 to 200 μm range. Using an aqueous solution of gelatin (optionally with <30% of low molecular weight alcohol) the fibers are ejected utilizing pressurized air emitted from nozzle and the non-woven formed directly from the emitted thin fibers. | 2009-09-03 |
| 20090220580 | Percutaneous Absorption Formulation - The present invention provides a percutaneous absorption formulation including a patch having an adhesive layer disposed on a substrate and the adhesive layer contains ketotifen fumarate and tris(hydroxymethyl)aminomethane, and the patch is packaged in a hygroscopic packaging material. In the percutaneous absorption formulation, tris(hydroxymethyl)aminomethane particularly selected from various basic substances is incorporated, and by packaging the patch in a hygroscopic packaging material, the percutaneous absorptivity and content stability of a drug can be simultaneously improved and the yellowing of the drug can be suppressed. These effects can be further improved by the incorporation of propyl gallate, the use of an adhesive layer including an SIS-based adhesive base and a rosin ester-based adhesion imparting resin, and/or the removal of oxygen from the atmosphere in the inside of the packaging material. | 2009-09-03 |
| 20090220581 | METHODS OF REDUCING INFLAMMATION AND MUCUS HYPERSECRETION - Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed. | 2009-09-03 |
| 20090220582 | METHOD OF CANCER TREATMENT USING SIRNA SILENCING - The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions. | 2009-09-03 |
| 20090220583 | Method and composition for treating inflammatory disorders - There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier. | 2009-09-03 |
| 20090220584 | Amphoteric Liposome Formulation - The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer. | 2009-09-03 |
| 20090220585 | Biological Active Blood Serum Fraction S-1-10, Methods for Producing It and Uses Thereof - The present invention relates to a method for preparing a biological active fraction of blood serum, the biological active fraction (S-1-10) and a pharmaceutical composition comprising said fraction as well as uses thereof in the treatment of various diseases and conditions, in particular seizures, cardiovascular diseases and proliferative diseases. | 2009-09-03 |
| 20090220586 | PROTEOMIMETIC COMPOUNDS AS INHIBITORS OF THE INTERACTION OF NUCLEAR RECEPTOR WITH COACTIVATOR PEPTIDES - The present invention relates to compounds, pharmaceutical compositions and methods which inhibit the binding of coactivator proteins in nuclear receptors, including estrogen receptors (alpha and/or beta), androgen receptors, thyroid receptors and peroxisome proliferators-activated receptors, among others. Compounds according to the present invention may be useful in the treatment of a variety of disease states or conditions which are mediated through nuclear receptors. | 2009-09-03 |
| 20090220587 | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands - A receptor ligand is conjugated to a lipid-soluble moiety, thereby allowing effective delivery of the peptide ligand to a target cell in the form of a liposome complex. The ligand brings the liposome in proximity to the target cell, facilitating the fusion of the liposome with an endosome of the cellular target to release the payload into the cytoplasm. The liposome itself packages drugs or other therapeutics that are delivered to the interior of the cell upon fusion of the liposome. | 2009-09-03 |
| 20090220588 | Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity - The compositions and methods of the present invention relate to the co-delivery of a molecule and a polypeptide to cells to improve the therapeutic efficacy of the molecules. In one embodiment of the invention, the invention may improve delivery of growth factors by co-delivering these growth factors with their receptors and co-receptors, such as syndecans. Co-delivery of growth factors with syndecans, for example, may protect growth factors from proteolysis, enhance their activity, and target the growth factors to the cell surface to facilitate growth factor signaling. This novel approach to growth factor therapy could be extended to other systems and growth factors enabling the enhancement of multiple signaling pathways to achieve a desired therapeutic outcome. | 2009-09-03 |
| 20090220589 | TREATMENT, DIAGNOSTIC, AND METHOD FOR DISCOVERING ANTAGONIST USING SPARC SPECIFIC MIRNAS - miRNAs that regulate human SPARC and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, ds miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. | 2009-09-03 |
| 20090220590 | Triple drug combinations for psychiatric patients - The mega capsule can be prescribed by any physician, and in particular those professionals in the psychiatric field. The mega capsule will be a form of medication designed for a specific patient in mind. The capsule will help the patients understand their medications better and make it easier for them to take. The patient may only have to take the mega capsule once or twice a day and by doing that, the patient will feel more in control of their prescriptions. By inventing the mega capsule, we may lower the cost significantly for the patients. Altogether, it will make life easier for the patients and the physicians. | 2009-09-03 |
| 20090220591 | Pharmaceutical Compositions Comprising Non-Steroidal Antiinflammatory Drug, Antipyretic-Analgesic Drug and Proton Pump Inhibotor - The present invention relates to pharmaceutical compositions in the form of fixed combination comprising non-steroidal anti-inflammatory drug or its single enantiomers or salts thereof, antipyretic-analgesic drug and proton pump inhibitor or its single enantiomers or salts thereof. The invention also relates to processes for the preparation of such compositions. | 2009-09-03 |
| 20090220592 | PREPARATION FOR THE TREATMENT OF TINNITUS - The invention relates to the use of blueberry extract for the preparation of a therapeutic composition for oral administration for the treatment and prevention of tinnitus. | 2009-09-03 |
| 20090220593 | EXTENDED RELEASE DOSAGE FORMS OF QUETIAPINE - The present invention relates to multiple unit extended release dosage forms of quetiapine for oral administration, wherein each unit comprises a core containing quetiapine and one or more of pharmaceutically acceptable excipients coated with a rate-controlling coating and process for the preparation thereof. | 2009-09-03 |
| 20090220594 | Tablet of Paracetamol Containing an Encapsulated Flavorant - A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink. | 2009-09-03 |
| 20090220595 | COMBINATION OF ERYTHROPOIETIN GLYCOISOFORMS - This invention relates to a combination of erythropoietin glycoisoforms, wherein such glycoisoforms may include a quantity of sialic acid ranging from 4 to 10 molecules of sialic acid per molecule of erythropoietin. The combination of glycoisoforms can be used for the treatment or prevention of sepsis, and used to prepare a pharmaceutical composition including such combination. The invention also encompasses a cell line producing a combination of erythropoietin glycoisoforms, procedures to obtain the cell line, a procedure to produce such a combination of glycoisoforms, and methods of treatment and prevention of sepsis. | 2009-09-03 |
| 20090220596 | Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix - A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms. | 2009-09-03 |
| 20090220597 | RAPID RELEASE IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose. | 2009-09-03 |
| 20090220598 | Stable Oral Pharmaceutical Composition Containing Thyroid Hormone Receptor Agonists - Compositions are described in which certain thyroid hormone receptor-binding compounds are formulated together with either an enteric coating, an antioxidant, or both an enteric coating and an antioxidant. Such formulation acts to prevent the formation of undesired reaction products in vivo. | 2009-09-03 |
| 20090220599 | Antifungal formulation and manufacturing method thereof - A new antifungal formulation is provided. The present invention uses a sterol modified with polyethylene glycol (PEG) as a drug carrier. The drug carrier encapsulates Amphotericin B (AmB) by self-assembly to form polymeric micelles. The polymeric micelles can reduce toxicity of Amphotericin B and control release of Amphotericin B. The polymeric micelles of Amphotericin B are used as a new antifungal formulation. | 2009-09-03 |
| 20090220600 | ANTIMICROBIAL FILMS - A film consisting of a titanium dioxide host matrix comprising silver oxide nanoparticles. | 2009-09-03 |
| 20090220601 | Autologous Oral Grafts - The present invention provides autologous oral grafts that may be used, for example, to treat oral cavity disease characterized by inflamed or damaged oral mucosa tissue, or to treat oral caries characterized by damaged enamel, dentin, or cementum. In certain embodiments, the autologous oral grafts comprise a biocompatible matrix and cultured oral cells (e.g., keratinocytes) from the patient to be treated. In certain embodiments, the cultured oral cells comprise an expression vector comprising a nucleic acid sequence encoding a therapeutic polypeptide configured to at least partially reduce the patient's oral mucosa tissue inflammation or damage. In particular embodiments, the oral disease is characterized by infiltration of the oral mucosa with activated, maturing dendritic cells. | 2009-09-03 |
| 20090220602 | SUBLIMABLE SUSTAINED RELEASE DELIVERY SYSTEM AND METHOD OF MAKING SAME - The invention relates to compositions suitable for the delivery and/or stabilization of biologically active substances. The compositions comprise a sublimable matrix material and the biologically active agent to be delivered. The compositions can be used as drug delivery systems to treat a wide variety of diseases or as systems for the protection and stabilization of such substances. Also disclosed are methods for preparing compositions of the present invention. | 2009-09-03 |
| 20090220603 | USE OF RHAMNOLIPIDS IN WOUND HEALING, TREATING BURN SHOCK, ATHEROSCLEROSIS, ORGAN TRANSPLANTS, DEPRESSION, SCHIZOPHRENIA AND COSMETICS - Various methods are provided, including wound healing with reduced fibrosis, treatment of burn shock, treatment and prevention of atherosclerosis, prevention and treatment of organ transplant rejection, treatment of depression and schizophrenia and treatment of the signs of aging, such as wrinkles, each of which uses administration of a composition containing one or more rhamnolipids as an active ingredient. | 2009-09-03 |
| 20090220604 | AMINO ACIDS IN MICELLE PREPARATION - Formulations are formed of a diblock copolymer (X—Y) having a hydrophilic block X comprising residues of monomer x, and a hydrophobic block Y comprising residues of monomer y; an additive selected from an amino acid and an oligopeptide. Upon admixture with water, the formulations form drug delivery vehicles, preferably in micellar form. The inclusion of amino acid and/or oligopeptide provides for the formation of micelles at an enhanced rate, and/or provides the formation of micelles having an enhanced ability to incorporate drug(s), and/or provides the formation of micelles having advantageous physical characteristics. | 2009-09-03 |
| 20090220605 | BONE MATRIX COMPOSITIONS HAVING NANOSCALE TEXTURED SURFACES - Bone matrix compositions having nanoscale textured surfaces and methods for their production are provided. In some embodiments, bone matrix is prepared for implantation and retains nanoscale textured surfaces. In other embodiments, nanostructures are imparted to bone matrix wherein collagen fibrils on the surface of the bone matrix have been compromised, thus imparting a nanoscale textured surface to the bone matrix. Generally, these methods may be applied to mineralized or demineralized bone including partially or surface demineralized bone. | 2009-09-03 |
| 20090220606 | TREATMENT AND PREVENTION OF ABNORMAL CELLULAR PROLIFERATION - This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of O-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanism (e.g. loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors); (2) benign and malignant cells of other proliferative disease in which aberrant cellular proliferation occurs; (3) aberrant smooth muscle cell proliferation, such as might occur following treatment for coronary atherosclerosis such as angioplasty or the insertion of a stent into an occluded vessel. | 2009-09-03 |
| 20090220607 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Described herein are polymeric compositions having a polymer residue and a crosslinker residue, wherein the polymer residue is bonded to the crosslinker residue with a moiety formed from a cycloaddition reaction. Also, described are methods of making and using such polymeric compositions. | 2009-09-03 |
| 20090220608 | PHARMACEUTICAL COMPOSITION OF MICROSPHERES FOR PREVENTING DIABETIC FOOT AMPUTATION - The present invention relates to a pharmaceutical composition that comprises polymeric microspheres containing epidermal growth factor (EGF) for the application, by the parenteral route, into the lower limbs of diabetic patients with cutaneous chronic ischemic ulcerative wounds. The pharmaceutical composition described herein, in contrast with the state of the art, is useful because reduce the administration frequency during the treatment and allows for the healing of the ulcerative wounds in a shorter time interval with respect to the injection of equivalent quantities of non-encapsulated EGF. | 2009-09-03 |
| 20090220609 | PROCESS TO CONTROL PARTICLE SIZE - A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10 μm and with a narrow, reproducible distribution of median particle sizes. | 2009-09-03 |
| 20090220610 | Suspension Comprising Benzimidazole Carbamate and a Polysorbate - This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 nm and a TWEEN-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and a method for protecting an animal from a parasitic infection. | 2009-09-03 |
| 20090220611 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same - The invention concerns microparticulate systems with modified release of oral active principle(s). The invention aims at providing a novel pharmaceutical with time-dependent and pH-dependent release mechanism, enabling: a) the latent period preceding the release of the active principle in the stomach; b) the pH triggering the release of the active principle in the intestine; c) the release speed of the active principle. This is achieved through the use of coated microparticles made from particles of active principle each coated with two coating films A and B. A comprises: film-forming (co)polymer (A1) insoluble in fluids of the gastrointestinal tract; ethylcellulose (co)polymer (A2) soluble in fluids of the gastrointestinal tract; plasticizing polyvinylpyrrolidone (A3); castor oil/optionally a surfactant and/or magnesium stearate lubricant (A4). B comprises a hydrophilic polymer (B1) bearing ionized groups with neutral pH (EUDRAGIT® L100-55) and a hydrophobic compound (B2) (LUBRITAB®). The invention also concerns medicines based on said microparticles. | 2009-09-03 |
| 20090220612 | HOLLOW-FIBRE-BASED BIOCOMPATIBLE DRUG DELIVERY DEVICE WITH ONE OR MORE LAYERS - A biocompatible drug delivery device in which the mean pore size in one or more layers is less than 100 μm. The device may be a hollow fibre or a membrane comprising a number of hollow fibres or a microsphere. The invention also extends to a method for preparing porous hollow fibres or microspheres, to the apparatus for preparing said fibres and to the use of the fibres as drug delivery devices. | 2009-09-03 |
| 20090220613 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT - A controlled release delivery device for controlled release of an active ingredient comprising: (i) a core particle comprising the active ingredient homogenously dispersed or dissolved therein; and (ii) an organosol polymeric coat comprising a homogenous mixture of, (a) a water soluble gel forming polymer and a water insoluble organosoluble polymer in a dry weight ratio of from about 20:80 to about 50:50, (b) an organosolvent, and (c) an anti-tacking agent; the organosol polymeric coal being applied directly to and substantially enveloping the core particle. | 2009-09-03 |
| 20090220614 | Thermo-Responsive Block Co-Polymers, and Use Thereof - Provided are thermo-responsive polymersomes, which display cold-controlled encapsulation near the physiological temperatures, and have a PDI less than 1.2. Morphology of the thermo-responsive polymersomes is a function of the weight fraction of the hydrophilic block in the block copolymer and the number average molecular weight (M | 2009-09-03 |
| 20090220615 | Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials - Novel main chain acid degradable polymer backbones and drug delivery systems comprised of materials capable of delivering bioactive materials to cells for use as vaccines or other therapeutic agents are described. The polymers are synthesized using monomers that contain acid-degradable linkages cleavable under mild acidic conditions. The main chain of the resulting polymers readily degrade into many small molecules at low pH, but remain relatively stable and intact at physiological pH. The new materials have the common characteristic of being able to degrade by acid hydrolysis under conditions commonly found within the endosomal or lysosomal compartments of cells thereby releasing their payload within the cell. The materials can also be used for the delivery of therapeutics to the acidic regions of tumors and other sites of inflammation. | 2009-09-03 |
| 20090220616 | MOISTURIZING AND LUBRICATING COMPOSITIONS - The present invention is generally directed to moisturizing and lubricating compositions for use on the bodyfacing surface of an absorbent product or on one or both faces of a tissue product. The moisturizing and lubricating compositions comprise an emollient, a humectant, and immobilizing agent and a compatibilizing agent. Optionally, the moisturizing and lubricating compositions can comprise a dispersing agent. | 2009-09-03 |
| 20090220617 | METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTERINE EXHAUSTION - The present invention relates to a method of facilitating the birth process of placental mammals, especially to a method of reducing delays in the birth process and, thereby, complications resulting there from that may negatively affect the health and wellbeing of the mother and increase the incidence of stillbirths and/or neonatal mortality. According to the present invention delays in parturition that result from maternal and/or uterine exhaustion may be prevented or reduced by the administration of an effective amount of one or more psychomotor stimulants to the parturient mammal prior to and/or during parturition. Said psychomotor stimulant is selected from the group comprising xanthines and amphetamines. | 2009-09-03 |
| 20090220618 | PHARMACEUTICAL FORMULATIONS COMPRISING POLYANIONIC MATERIALS AND SOURCE OF HYDROGEN PEROXIDE - A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises at least a polyanionic material and at least a source of hydrogen peroxide. The formulation can comprise an ophthalmically active agent for treating or controlling a disease or disorder of the eye. | 2009-09-03 |
| 20090220619 | NUTRITIONAL FORMULATION - The present invention relates to nutritional supplements that provide an adult with essential vitamins and minerals that may be lacking in the adult's diet and prevent chronic diseases, such as osteoporosis. A number of combinations of nutrients in set ratios are provided to increase the body's ability to absorb and use the nutrients. These combinations are important in helping the body reach the proper balance required for maximized function. Because adults over the age of 50 years have different nutritional needs, nutritional supplements specifically designed for them are also provided. | 2009-09-03 |
| 20090220620 | Functional Fluid and a Process for the Preparation of the Functional Fluid - A functional fluid for the removal of contaminates such as but not limited to, acid causing components in gas, sulfur components and carbon oxides from fluid streams, and removal and treatment of NO | 2009-09-03 |
| 20090220621 | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination - A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate. | 2009-09-03 |
| 20090220622 | USE OF MIMOSINE OR A DERIVATIVE THEREOF FOR TREATING THE CUTANEOUS EFFECTS OF PSORIASIS AND RELATED SKIN DISORDERS, AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to the use of mimosine or a derivative thereof for treating the cutaneous effects of psoriasis and related skin disorders. | 2009-09-03 |
| 20090220623 | NOVEL HERBAL ACNE CONTROL COMPOSITION, METHOD OF MANUFACTURING THE SAME AND USE THEREOF - Disclosed herein a novel herbal acne control compositions comprising extracts of | 2009-09-03 |
| 20090220624 | COMPOSITIONS COMPRISING APOCYNIN, GINKGO AND GINGER AND USES THEREOF - A composition comprising ginkgo biloba or extract or component thereof; apocynin; and a gingerol. The composition may be used to treat diseases such as CF and COPD. | 2009-09-03 |
| 20090220625 | SYNERGISTIC MIXTURES OF BISABOLOL AND GINGER EXTRACT - Described is a formulation having a skin irritation-reducing action consisting of or comprising: bisabolol and a composition or compound chosen from the group consisting of a) substance mixtures obtainable from an extraction of ginger, b) substance mixtures obtainable from a separation of a ginger extract which comprise a compound which is chosen from the group consisting of gingerols, shogaols, gingerdiols, dehydrogingerdiones, paradols and derivatives thereof and c) compounds obtainable from a separation of a ginger extract which are chosen from the group consisting of gingerols, shogaols, gingerdiols, dehydrogingerdiones, paradols and derivatives thereof and mixtures thereof, wherein the particular content of bisabolol and of the said composition or compound in the formulation is adjusted such that the skin irritation-reducing action of these contents is increased synergistically. | 2009-09-03 |
| 20090220626 | GRAPE SEED EXTRACT AND ITS CONSTITUENTS FOR USE AS CYP2A6 INHIBITORS - The present invention relates to a use of grape seed extract or its constituents to treat conditions which benefit from an inhibition of cytochrome P450 2A6 (CYP2A6). In particular conditions which benefit from the inhibition of CYP2A6 are conditions which benefit from decreased metabolism of nicotine to cotinine, for example, preventing, reducing or treating smoking, and conditions which benefit from a decrease in the in vivo formation of carcinogens, for example prevention or treatment of cancer. | 2009-09-03 |
| 20090220627 | NOVEL VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION INHIBITORS - The invention provides anti-aging agents, angiogenesis inhibitors and vascular endothelial growth factor (VEGF) expression inhibitors containing one or more galenicals selected from the group consisting of mukurossi peel extract, hazelnut extract, linden extract, | 2009-09-03 |
| 20090220628 | APPARATUS AND METHOD FOR CONTROLLING SERVOMOTOR OF ELECTRIC INJECTION MOLDING MACHINE - An apparatus and method for servomotors of an electric injection molding machine includes a motion controlling unit, two driving amplifying units, and two servomotors respectively connected to the driving amplifying units. The motion controlling unit includes two servomotor position controllers both for receiving a first position command, and the driving amplifying units are respectively connected to the servomotor position controllers for receiving a second and third position command. Two position detectors are respectively received in the two screw caps that are mounted to the servomotors for detecting absolute positions of the corresponding screw caps. The screw caps are respectively connected to inputs of the first and second servomotor position controllers to form two screw cap position feedback circuits. The values of the screw cap position feedback circuits are compared to the first position command for being input into the driving amplifying units to drive the corresponding servomotors to act synchronously. | 2009-09-03 |
| 20090220629 | MOLDING APPARATUS INCORPORATING PRESSURE UNIFORMITY ADJUSTMENT - A molding apparatus comprises first and second mold chases that are configured to clamp an electronic device therebetween, and a driving mechanism which drives the first and second mold chases to apply a clamping force onto the electronic device. A pressure adjustment mechanism communicates with at least one of the mold chases and applies an additional clamping pressure onto one or more portions of the mold chase. The pressure adjustment mechanism comprises movable supports that are displaceable in directions which are substantially perpendicular to the direction of the clamping force so as to transmit and apply the said additional clamping pressure onto the mold chase, and also a plurality of piezoelectric actuators which are operative to apply displacement forces to the movable supports in their displacement directions. | 2009-09-03 |
| 20090220630 | METHOD OF CONTROLLING THE OPENING AND CLOSING OF A BLOW MOLD AND BLOWING DEVICE FOR IMPLEMENTING SAME - A molding device for manufacturing thermoplastic containers by blow-molding or stretch-blow-molding heated parisons. The molding device having a blow-molding mold of the hinged mold type with at least two mold halves which can be separated from one another by rotation about a common axle of articulation under the action of an actuating device. The actuating device is designed in such a way that the two mold halves have respective angles of opening on each side of the parting plane of the mold which are not equal. | 2009-09-03 |
| 20090220631 | POSITIONING DEVICE WITH BEARING MECHANISM - A positioning device includes a first member and a second member. The first member defines an alignment axis and has a male portion. The second member is separable from the first member and defines a female portion for mating with the male portion along the alignment axis. A bearing mechanism is coupled to the female portion for reducing friction when the male and female portions mate and the bearing mechanism moves between first and second positions relative to at least one of the members. A resilient member is retained by the second member for resiliently supporting the bearing mechanism between the first and second positions. A retaining pin is coupled to the bearing mechanism and is retained between the second member and the resilient member. The retaining pin reacts against the resilient member as the bearing mechanism moves between the first and second positions. | 2009-09-03 |
| 20090220632 | Hot Runner Nozzle System - A hot runner nozzle system ( | 2009-09-03 |
| 20090220633 | Methods of making extrusion dies - Methods for making extrusion dies using a LIGA process, a German acronym for lithography (Lithographie), electroplating (Galvanoformung), and molding (Abformung), are described. The resulting extrusion dies can be used, for example, for extrusion of cellular ceramic substrates, precision extrusion of optical fiber or optical fiber precursors, or other applications where profile extrusion requires high dimensional precision and/or has otherwise intricate patterns. | 2009-09-03 |
| 20090220634 | Injection Molding Apparatus with Replaceable Gate Insert - Injection molding apparatus has upper and lower mold halves that split along the center line of the parison cavity and the gate passage leading thereto. Each hot melt injection nozzle is received within a tubular insert cup having a reduced diameter tip that is seated within the gate passage. The cup is supported on the lower mold half so as to remain thereon as the upper mold half opens and closes the mold. The base end of each nozzle has a swivel ball and socket relationship with the manifold block which supplies it with hot melt, while the tip end of each injection nozzle is configured to permit swivelling within the insert cup as need be to accommodate dimensional changes that arise during non-uniform thermal expansion and contraction of different parts of the tooling. | 2009-09-03 |
| 20090220635 | HOT RUNNER AND MOLD ASSEMBLY USING SAME - A hot runner ( | 2009-09-03 |
| 20090220636 | Actuating Device for Shut-Off Needles in Injection Molding Machines Having Needle Valve Nozzles - The invention relates to an actuating device ( | 2009-09-03 |
| 20090220637 | NUTRITION FOR OBESE PATIENTS - This invention provides a composition and method for providing nutritional support to obese patients. The composition has an energy density between 0.4 and 0.9 kcal/ml and comprises a protein source which comprises at least 30% by weight whey protein and provides at least 30% of the total calories of the composition. The composition may include a carbohydrate source and a lipid source. Preferably, at least 50% by weight of the protein source is whey protein. The invention further extends to use of the composition in the prevention or treatment of malnutrition in obese patients. | 2009-09-03 |
| 20090220638 | Method for Producing Calcium Soaps for Animal Feed - The invention relates to a method for producing calcium soaps for animal feed. The invention consists of a novel process for producing calcium soaps, comprising the saponification of fats and natural oils with CaO, in which the reaction mass is heated and subjected to reduced pressure. In this way, calcium soaps with a fatty acid content of more than 80% can be obtained without requiring any subsequent washing or concentration process. Said high fatty acid content renders the soaps particularly suitable for use as a component of animal feed. The applicability of said soaps for feed for monogastric animals is improved by adding glycerol and/or another emulsifying agent during the soap production process. | 2009-09-03 |
